跳至主要内容
临床试验/CTRI/2024/02/063353
CTRI/2024/02/063353尚未招募3 期

To compare the efficacy and adverse effects of oral tofacitinib and oral methylprednisolone mini-pulse and combination of both in treatment of alopecia areata: A Randomized Controlled Trial.

Institute of Medical Sciences BHU1 个研究点 分布在 1 个国家目标入组 219 人开始时间: 2024年3月1日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
219
试验地点
1
主要终点
Reduction in severity of alopecia tool (SALT) score by 90%

研究概览

简要总结

All patients aged 18 to 65 years diagnosed clinically with alopecia areata coming to Dermatology OPD, SSH, BHU those who fulfill the inclusion criteria will be included in the study.  All patients will be randomized equally in three groups.Group A will be giventofacitinib 5 mgBD with supportive treatment (proton pump inhibitor, calcium and vitamin D) for 4 months.

Group B will be given oral methylprednisolone 32 mg on two consecutive days per week with supportive treatment (proton pump inhibitor, calcium and vitamin D)for 4 months.

Group C will be given both tofacitinib 5 mg BD and oral methylprednisolone 32 mg on two consecutive days per week with supportive treatment (proton pump inhibitor, calcium and vitamin D) for 4 months.

All patients will be followed every month for 7 months and response evaluation will be done by severity of alopecia tool (SALT) score. End point of treatment will be complete regrowth of hair or 4 months of treatment whichever achieved first.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Clinically diagnosed cases of alopecia areata with severity of alopecia tool (SALT) score of 10 % or over.
  • Age: 18 to 65 years
  • Patients not taking systemic drug in last 1 month and topical treatment in last 15 days.
  • All participants who give consent for the study.

排除标准

  • Patients having history or active tuberculosis.
  • Patients with Pregnancy and lactating mother.
  • Patients with uncontrolled renal, hepatic, hematological or heart disease.
  • Patients with diabetes mellitus and hypertension.

结局指标

主要结局

Reduction in severity of alopecia tool (SALT) score by 90%

时间窗: Reduction in severity of alopecia tool (SALT) score by 90% which will assessed monthly for 4 months.

次要结局

  • Reduction in severity of alopecia tool (SALT) score by 50% & reduction in severity of alopecia tool (SALT) score by 100%(Reduction in severity of alopecia tool (SALT) score by 50% & reduction in severity of alopecia tool (SALT) score by 100% which will be assessed monthly for 4 months.)

研究者

发起方
Institute of Medical Sciences BHU
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Satyendra Kumar Singh

Institute of Medical Sciences Banaras Hindu University

研究点 (1)

Loading locations...

相似试验